You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: ENGINEERING RESOURCES GROUP INC Topic: NIEHS
PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing CompoundsSBC: Initos Pharmaceuticals LLC Topic: NCATS
ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: AEROSOL DEVICES INC Topic: NIAID
Aerosolized pathogenssuch as Influenza virusescan spread rapidly and silently throughout a populationcausing severe outbreaks that can be difficult to controlEarly detection of these airborne pathogens is key to controlling outbreaksespecially among vulnerable populations such as in hospitalstreatment centers or nursing homesYet available methods are neither rapidnor portableCurrent methods rely h ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogenSBC: Arrevus, Inc. Topic: NIAID
Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's diseaseSBC: ASTROCYTE PHARMACEUTICALS INC. Topic: NIA
PROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: PHAGEPRO, INC. Topic: NIAID
PROJECT SUMMARY Cholera is an acute and severe disease caused by the bacterium Vibrio cholerae that is spread primarily through contaminated water sources due to a lack of adequate sanitation infrastructure. The World Health Organization estimates that there are at least 3 million cases globally per year, 40 percent of which are spread through household transmission. Current prevention methods req ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBI
Idiopathic pulmonary fibrosisIPFthe most common of the interstitial lung diseasesoccurs in aboutpeoplewithnew cases diagnosed annually in the USThe typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandaposof the lungs causing an irreversible loss of the tissueandapos s ability to transport oxygenCo morbid pulmonary hypertension is commonly seen in ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Establishing a mechanistic foundation for drug discovery: The ABCA4 transporter in Stargardt Disease and other retinopathiesSBC: Rectify Pharmaceuticals LLC Topic: NEI
ABCAis an ABC transporter found in retinal photoreceptor cellsMutations in ABCAhave been implicated in retinopathies such as autosomal recessive Stargardt macular degenerationcone rod dystrophyretinitis pigmentosa and age related macular degenerationABCAfunctions as an importerandflippasemoving N retinylidene phosphatidylethanolamineN retinylidene PEfrom the lumen to the cytoplasmic leaflet of dis ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOMARCK PHARMACEUTICALS, LTD Topic: NEI
ABSTRACT Uveitisthe most common form of intraocular inflammationaccounts forof preventable blindness in the USTreatment options are limited to cortiscosteroids and or immunosuppressantsbut both of these therapies show limited efficacy and are associated with numerous adverse and potentially serious side effectsNew therapeutic targets leading to effective and safe treatments are urgently requiredA ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: LYST THERAPEUTICS LLC Topic: NHLBI
SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health